finally, a semblance of balance tot he breathless ‘abnormal saline’ madness?
NephJC Shorts: zilebesiran silencing hypertension via RNA interference
CONFIDENCE manifests: finerenone & empagliflozin – CKD power couple that’s redefining ‘renal romance’
Check out CONFIDENCE recap
A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
CONFIDENCE Visual Abstract
Check out the beautiful visual abstract made by NephJC intern Michelle Fravel.
Resumen Visual Ensayo CONFIDENCE
El ensayo CONFIDENCE evaluó la combinación de finerenona + empagliflozina en ERC + DM2: mayor reducción de CACu a 180 días. ¿Estamos listos para iniciar la terapia combinada desde el principio?
Revisa el resumen visual por Michelle Fravel
NephJC Shorts: Salt reduction still lowers BP
NephJC Shorts: BedMed and Chronotherapy
Introducing NephJC Shorts
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for the time, such as the Google Hangouts. We want to try another such experiment, and hope we receive feedback to decide if this is something worthwhile that we should continue doing.
There are many studies and many trials and many reviews, and many guidelines that are published in Nephrology every week. Indeed, it is a golden era for randomized controlled trials in Nephrology. On the other hand, NephJC only occurs twice a month. It does take a lot of work, with the detailed critical appraisal, readable summary, visual, abstracts, and the chats. Sometimes the occasional, irregularly irregular podcast. Hence, we cannot deal with all the worthwhile studies that are coming out.
Enter NephJC Shorts.
This week, we are publishing a few short blogs. The purpose here is to cover some notable studies in brief. They do not receive the full, long, NephJC treatment. The articles we choose are those that the NephJC editorial team fancies, but suggestions are welcome. Since these are a shorter format, we don’t do a deep dive into the methods and don’t have a long list of the limitations and strengths. Think of them as a pithy version of the usual NephJC blog. Feedback welcome!
The NephJC Editors
CAPTIVATE NephTrials Visual Abstract
Check out the beautiful visual abstract made by Kajaree Giri
Do nudges increase the use of GDMT in diabetic CKD?
Is tacrolimus superior to MMF in pediatric steroid sensitive nephrotic syndrome?
From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Ensayo NUDGE-CKD: El Resumen Visual
El estudio NUDGE-CKD evaluó si enviar cartas electrónicas con recomendaciones a médicos y pacientes podía aumentar el uso de tratamientos clave en enfermedad renal crónica (iSRAA o iSGLT2).
Revisa el resumen visual por Divya Bajpal
¿El resultado? Hoy en vivo por #NephJC!
The NUDGE-CKD Visual Abstract
Check out the beautiful visual abstract made by NephJC faculty Dr Divyia Bajpai
Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
NephJC Internship Reforms and then Reforms
NephJC Bookclub returns on August 19th
Here at NephJC we know that the summer is a hard time to focus on medical minutia, it is a time to find a comfortable chair and lose yourself in a book so for the 11th year we are doing a book rather than journal club chat. This summer our community is going to read John Green’s Everything is Tuberculosis.
Book homepage: EverythingIsTB.com
Ensayo STAMP: ¿Tacrolimus o Micofenolato en el síndrome nefrótico pediátrico?
El síndrome nefrótico en niños puede implicar recaídas frecuentes, alta carga de esteroides y decisiones terapéuticas difíciles. Entonces, ¿cuál mantiene mejor la remisión: tacrolimus o micofenolato de mofetilo?
Revisa el VA y únete a la discusión en #NephJC
The STAMP Trial VA: Who Gets the Approval—TAC or MMF in Pediatric Nephrotic Syndrome?
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan